A spatial AI biomarker company specializing in deciphering cellular conversations and mapping cellular interactions within tissue samples to predict therapeutic outcomes has announced the expansion of its executive leadership team. Nucleai revealed today the appointment of Vikas Ahuja as Vice President of Strategic Partnerships. With over two decades of experience in life sciences, Ahuja’s role will involve establishing an ecosystem of partners, including diagnostic companies, contract research organizations (CROs), assay and instrument vendors, and software companies. This ecosystem will facilitate the deployment of Nucleai’s AI platform at scale for late-stage clinical trials and diagnostic applications.
Avi Veidman, CEO of Nucleai, expressed enthusiasm about Ahuja’s appointment, highlighting his extensive experience and knowledge in business development across various sectors within the life sciences industry. Veidman emphasized Ahuja’s suitability for the role, citing his proven track record in fostering strategic alliances and driving global growth initiatives.
Nucleai’s AI spatial technology is currently utilized in an active clinical trial to aid patient selection, reflecting a growing demand for AI spatial biomarkers to support the burgeoning pipeline of next-generation treatments. Ahuja’s expertise in building partnerships to scale the deployment of novel diagnostics is seen as instrumental in advancing Nucleai’s mission to power precision therapeutics with AI-driven spatial biomarkers and diagnostics.
Prior to joining Nucleai, Ahuja served as Vice President of Business Development & Strategy at Ambry Genetics, where he led corporate strategy, M&A activities, and licensing initiatives, and oversaw international business segments. His role involved establishing international partnerships across regions like Latin America, the Middle East, Southeast Asia, China, and Australia at Mallinckrodt Pharmaceuticals.
Ahuja expressed excitement about his new role, seeing it as an opportunity to leverage his experience in building impactful collaborations across the life sciences sector. He cited the recent partnership with GoPath Diagnostics as evidence of how strategic alliances can advance Nucleai’s mission of transforming patient care through advanced AI-driven spatial biomarkers. Ahuja looks forward to fostering similar partnerships to enhance relationships with large commercial and diagnostic companies, driving Nucleai’s innovative platform to new heights and ultimately improving patient outcomes.
Ahuja holds an MBA from The Wharton School of the University of Pennsylvania and an MS in Chemical Engineering from Imperial College, London.
